Financials
Financial year 2025
Dr. Christophe Van de Wiele - Nucleaire Geneeskunde from Merelbeke-Melle, company number BE0543311549, closed financial year 2025 with a result of € 268,956 after tax. For that financial year Dr. Christophe Van de Wiele - Nucleaire Geneeskunde recorded a gross margin of € 403,690 and equity of € 762,024. Compared with financial year 2024, the result moved from € 372,101 to € 268,956. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.
€ 762,024
▼ 6% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 268,956
▼ 28% vs 2024
Profit after tax over the fiscal year.
€ 98,581
▼ 49% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 317,100 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
€ 9,840
▼ 67% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 325,241
▼ 16% vs 2024
€ 54,733 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.
€ 10,993
▲ 51% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 31,510
▼ 5% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 437,019 | € 656,193 | € 572,411 | € 403,690 | ▼ 29% |
| Profit after taxes | € 268,458 | € 430,200 | € 372,101 | € 268,956 | ▼ 28% |
| Equity | € 437,868 | € 638,068 | € 810,169 | € 762,024 | ▼ 6% |
| Total debts | € 555,175 | € 475,247 | € 466,924 | € 407,835 | ▼ 13% |
| Cash | € 58,519 | € 53,258 | € 192,513 | € 98,581 | ▼ 49% |
| Land & buildings | € 624,883 | € 741,955 | € 717,557 | € 693,158 | ▼ 3% |
| Retained profit | € 432,868 | € 633,068 | € 805,169 | € 757,024 | ▼ 6% |
| Dividend | € 0 | € 230,000 | € 200,000 | € 317,100 | ▲ 59% |
| Bank debt | € 533,854 | € 453,561 | € 385,114 | € 325,241 | ▼ 16% |
| Balance sheet total | € 993,043 | € 1,113,315 | € 1,277,093 | € 1,169,859 | ▼ 8% |
Key figures of Dr. Christophe Van de Wiele - Nucleaire Geneeskunde, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Dr. Christophe Van de Wiele - Nucleaire Geneeskunde?
What happened at Dr. Christophe Van de Wiele - Nucleaire Geneeskunde in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 268,956 (▼ 28% vs 2024). Source: NBB ↗
- New establishment in Kortrijk. KBO
- Start of the company according to the CBE. KBO
In short
From € 268,458 profit in 2022 to € 268,956 profit in 2025.
Paid € 432,726 in corporate taxes since 2022.
Best year ever: 2023, with € 430,200 profit.
Paid out € 747,100 in dividends to the owners in total.
A new publication or filing at Dr. Christophe Van de Wiele - Nucleaire Geneeskunde? We notify you, reason included.
Follow Dr. Christophe Van de Wiele - Nucleaire GeneeskundeDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Dr. Christophe Van de Wiele - Nucleaire Geneeskunde are Charlotte De Schepper and Christophe Van de Wiele. Christophe Van de Wiele is also behind Nuc. Gen. K., Gallery 2Move and M-VDW.
Directors
According to the 2025 annual accounts
Charlotte De Schepper
Director
Establishments
Establishment units
Physical locations of this company
Geraardsbergsevoetweg 9
9820 Merelbeke-Melle
President Kennedylaan(Kor) 4
8500 Kortrijk
Active since 12 December 2013
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0543.311.549
- VAT number
- BE 0543.311.549
- Registered office
- Geraardsbergsevoetweg 9, 9820 Merelbeke-Melle
- Names & denominations
- Dr. Christophe Van de Wiele - Nucleaire Geneeskunde
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 12 December 2013
- Peppol
- Active · Active since 14 Nov 2024